"The company on February 11 announced it had raised $100 million in Series C funding as it pursues FDA approval of LOY-002, a beef-flavored daily prescription pill designed to extend the healthy lifespan of senior dogs. The drug mimics some of the effects of a calorie-restricted diet in addressing age-related metabolic issues without requiring pet owners to cut their dogs' food supply or curbing canine appetites."
""People do not want their dogs to not have food motivation, because that's how you train dogs," says Loyal founder and CEO Celine Halioua. "How we domesticated dogs was sharing meals with them; losing that can actually really impact the dog-human bond." But, of course, people do want to share that bond longer than the typical canine lifespan allows. Halioua started Loyal in late 2019 after a stint as chief of staff at The Longevity Fund, a lifespan-focused investment fund founded by Laura Deming and an early backer of Loyal."
Loyal has raised more than $250 million in total funding, including a $100 million Series C, to develop canine longevity drugs. LOY-002 is a beef-flavored daily prescription pill intended to extend the healthy lifespan of senior dogs by mimicking some effects of calorie restriction on age-related metabolic issues without requiring reduced food intake. The company is pursuing FDA expanded conditional approval and hopes to submit the final requirement this year. Loyal was founded in late 2019 by Celine Halioua, who sees canine trials as faster, tractable models that could inform human longevity treatments. LOY-002 is one of three medications in development.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]